Wensheng Zhang

Dr. Wensheng Zhang


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Molecular Therapy
Verified
Journal Article
Open access
SZShuai Zhang
Shuai Zhang
DZDina Zhu
Dina Zhu
HLHong Li
Hong Li
HLHejian Li
Hejian Li
CFChengqiang Feng
Chengqiang Feng
WZWensheng Zhang
Wensheng Zhang
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. Although many researchers have attempted to explain the origins of AD, developing an effective strategy in AD clinical therapy is difficult. Recent studies have revealed a potential link between AD and circRNA-associated-ceRNA networks. However, few genome-wide studies have identified the potential circRNA-associated-ceRNA pairs involved in AD. In this study, we systematically explored the circRNA-associated-ceRNA mechanism in a 7-month-old senescence-accelerated mouse prone 8 (SAMP8) model brain through deep RNA sequencing. We obtained 235 significantly dysregulated circRNA transcripts, 30 significantly dysregulated miRNAs, and 1,202 significantly dysregulated mRNAs. We then constructed the most comprehensive circRNA-associated-ceRNA networks in SAMP8 brain. GO analysis revealed that these networks were involved in regulating the development of AD from various angles, for instance, axon terminus (GO: 0043679) and synapse (GO: 0045202). Following rigorous selection, we discovered that the circRNA-associated-ceRNA networks in this AD mouse model were mainly involved in the regulation of Aβ clearance (Hmgb2) and myelin function (Dio2). This research is the first to provide a systematic dissection of circRNA-associated-ceRNA profiling in SAMP8 mouse brain. The selected circRNA-associated-ceRNA networks can profoundly affect the diagnosis and therapy of AD in the future.

1 February 2015 in Neuropharmacology
Verified
Journal Article
Closed access
LCLv Cui
Lv Cui
LWLei Wang
Lei Wang
XLXiaoli Liu
Xiaoli Liu
SYShijun Yan
Shijun Yan
SYShirley ShiDu Yan
Shirley ShiDu Yan
WZWensheng Zhang
Wensheng Zhang

1 December 2016 in European Journal of Pharmacology
Verified
Journal Article
Closed access
GCGuoqiong Cao
Guoqiong Cao
PSPing Su
Ping Su
SZShuai Zhang
Shuai Zhang
LGLimin Guo
Limin Guo
HZHaijing Zhang
Haijing Zhang
WZWensheng Zhang
Wensheng Zhang

22 September 2014 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
DZDina Zhu
Dina Zhu
LWLei Wang
Lei Wang
QZQile Zhou
Qile Zhou
SYShijun Yan
Shijun Yan
ZLZhi Li
Zhi Li
WZWensheng Zhang
Wensheng Zhang

20 November 2019 in Aging
Verified
Journal Article
Open access
SZShuai Zhang
Shuai Zhang
HLHejian Li
Hejian Li
LZLing Zheng
Ling Zheng
HLHong Li
Hong Li
CFChengqiang Feng
Chengqiang Feng
WZWensheng Zhang
Wensheng Zhang
Transfer RNA-derived fragments (tRFs) are known to contribute to multiple illnesses, including cancers, viral infections, and age-related neurodegeneration. In this study, we used senescence-accelerated mouse prone 8 (SAMP8) as a model of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease, and a control, the senescence-accelerated mouse resistant 1 (SAMR1) model, to comprehensively explore differences in tRF expression between them. We discovered 570 tRF transcripts among which eight were differentially expressed. We then obtained 110 potential target genes in a miRNA-like pattern. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotation suggest that these target genes participate in a variety of brain functions; e.g., synapse formation (GO: 0045202) and the synaptic vesicle cycle pathway. We further assessed in detail those tRFs whose miRNA-like pattern was most likely to promote the progression of either Alzheimer's or Parkinson's disease, such as AS-tDR-011775 acting on Mobp and Park2. Our findings suggest the eight dysregulated tRFs we uncovered here may be beneficially exploited as potential diagnostic biomarkers and/or therapeutic targets to treat age-related brain diseases.